Skyrizi treats moderatesevere psoriasis and falls into the same class of drugs as Ilumya and Tremfya. Skyrizi is intended to fill the void anticipated as the company’s current blockbuster Humira loses its patent protection and interrupts their revenue stream.

Skyrizi requires 2 injections at the same time but at different sites. Initial treatment should be followed by further injections 4 weeks later with subsequent injections every 12 weeks. The skin clears completely or almost totally by 4 months in about 8090% of individuals but some loss of improvement occurs over time.

The cash price for the first year of Skyrizi exceeds $88,000.00 with this inconceivable number falling to $59,000.00 afterward. Out of necessity the company will negotiate special under the table discounts with pharmacy benefit managers and offer consumers copay cards. Otherwise the price is unaffordable.